Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558081 | 1.00 | PDPK1 (0.38) | PDPK1SYKLMNAKMT2AAAK1 | |
| SCHEMBL3592339 | 0.86 | GRM5 (0.36) | PDPK1LMNAKMT2AAAK1ATR | |
| SCHEMBL3804334 | 0.85 | GRM5 (0.33) | PDPK1LMNAKMT2AAAK1ATR | |
| SCHEMBL23025029 | 0.81 | SSTR4 (0.36) | PDPK1SYKAAK1USP30 | |
| SCHEMBL15274739 | 0.81 | PDPK1 (0.40) | PDPK1SYKMAP4K4USP30 | |
| SCHEMBL14017748 | 0.79 | MT-CO2 (0.39) | MT-CO2 | |
| SCHEMBL29070858 | 0.79 | JAK3 (0.40) | PDPK1SYK | |
| SCHEMBL8819730 | 0.79 | PDPK1 (0.35) | PDPK1SYKUSP30FGFR4 | |
| SCHEMBL30855200 | 0.79 | PDPK1 (0.35) | PDPK1SYKUSP30 | |
| SCHEMBL6107019 | 0.79 | GRM5 (0.34) | GRM5FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024159094-A1 | PYRIMIDINYL (HETERO)AROMATIC AMINOPYRIDINE COMPOUNDS FOR INHIBITION OF RAF KINASES | ENLIVEN INC. (US) | 2024-08-02 | — | — | WO | disclosed |
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200296-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (HK) | 2023-06-28 | — | — | EP | disclosed |
| CN-110183449-B | Mnk inhibitors and methods related thereto | 效应治疗股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| WO-2022038563-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (CN) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | PDPK1 130/4885SYK 686/4885LMNA 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.